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============

Voltage-gated sodium (Na~v~) channels are essential for the rapid depolarization phase of action potential and play a key role in the electrical signaling in most excitable cells. Structurally, Na~v~ channels are composed of one α subunit and one or more β subunits. The α subunit contains two functionally distinct structural entities, namely, the voltage-sensing domains (VSDs) and the ion-conducting pore domain (Catterall, [@CR5], [@CR6]). The β subunits, which bind to α subunit covalently or non-covalently, modulate membrane trafficking, voltage dependence, and channel gating kinetics (Catterall, [@CR5], [@CR6]). In mammals, Na~v~ channels have nine known α members distributed in different excitable tissues. Specifically, Na~v~1.1, Na~v~1.2, Na~v~1.3, and Na~v~1.6 are the primary sodium channels in central nervous system (CNS), Na~v~1.4 is primarily expressed in skeletal muscle, Na~v~1.5 is mainly expressed in heart, and Na~v~1.7, Na~v~1.8, and Na~v~1.9 are mainly distributed in peripheral nervous system (Plummer and Meisler, [@CR50]; Goldin, [@CR26]; Catterall et al., [@CR7]).

All α subunits share nearly identical structure topology---a canonical voltage-gated ion channel fold with four homologous repeats, each containing six transmembrane segments S1--S6. Specifically, S5--S6 segments form the pore domain that conducts selective sodium filtering, while S1--S4 segments constitute the voltage-sensing domain that controls voltage-dependent gating (Catterall, [@CR3]). The voltage sensors in the VSDs are featured by a number of positively charged amino acids (arginine or lysine) located at every third position in the S4 segment. Upon membrane depolarization, movements of these charged residues in the S4 segment are coupled to the opening of the pore domain and the subsequent influx of sodium ions across cell membrane. The pore domain is structurally organized with a four-fold pseudo-symmetry. The pore (P) loops, which are supported by the P1 helix (corresponding to the P helix in potassium channel) and P2 helix between S5 and S6 segments in each repeat, constitute the selectivity filter (SF) (Corry and Thomas, [@CR13]). Four amino acid residues (aspartate, glutamate, lysine, and alanine, DEKA, in repeats I, II, III, and IV, respectively) in the P loops are crucial for sodium selectivity. Mutating these residues to glutamates confers calcium selectivity, suggesting that the side chains of these amino acids are likely to interact directly with the sodium ions to determine ion selectivity (Heinemann et al., [@CR30]; Sun et al., [@CR55]).

Na~v~ channels inactivate rapidly. A cluster of hydrophobic amino acids (isoleucine, phenylalanine, methionine, and threonine), namely the IFMT motif, located in the cytosolic regions of domain III and domain IV, are required for rapid inactivation. This is demonstrated by the fact that rapid inactivation could be achieved by titrating small peptides containing the IFMT motif (Vassilev et al., [@CR61]; West et al., [@CR65]).

Sodium channelopathies are a group of diseases caused by defective Na~v~ channels, either, in most cases, of congenital nature or acquired nature (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}, [9](#Tab9){ref-type="table"}, [10](#Tab10){ref-type="table"}) (George, [@CR25]; Catterall, [@CR4]; Kim, [@CR34]). For example, Na~v~1.1 is primarily expressed in the soma of neuronal cells in the CNS, and mutations of Na~v~1.1 cause GEFS+2 (generalized epilepsy with febrile seizures plus 2) (Catterall et al., [@CR8]). Moreover, mutations of Na~v~1.1 are also the main causes of EIEE6 (epileptic encephalopathy, early infantile, 6) and ICEGTC (intractable childhood epilepsy with generalized tonic-clonic seizures) (Escayg and Goldin, [@CR18]). Na~v~1.5 is the major sodium channel expressed in heart. Na~v~1.5 mutations may lead to various cardiac diseases such as LQT3 (long QT syndrome 3), BRGDA1 (Brugada syndrome 1), and SSS1 (sick sinus syndrome 1) (Olson et al., [@CR48]; Song and Shou, [@CR54]; Veerman et al., [@CR63]). Na~v~1.7 is preferentially expressed in the sympathetic neurons, olfactory epithelium, and dorsal root ganglion sensory neurons, and plays a cardinal role in pain transmission (Djouhri et al., [@CR17]; Dib-Hajj et al., [@CR16]). Gain-of-function mutations of Na~v~1.7 are implicated in two distinct paroxysmal pain syndromes---IEM (primary erythermalgia) and PEPD (paroxysmal extreme pain disorder), while loss-of-function mutations of Na~v~1.7 inflict people with CIP (indifference to pain, congenital, autosomal recessive) (Lampert et al., [@CR37]; Dib-Hajj et al., [@CR16]). In all, Na~v~ channel mutations play a central role in the pathophysiology of sodium channelopathies. Pharmacologic modulation of Na~v~ channels may thereby represent a viable therapeutic approach for the treatment of many neurological disorders such as epilepsy, arrhythmia, and pain.Table 1Structural mapping of disease-related mutations identified in human Na~v~1.7Related proteinsMutationsDiseasesStructural positionMap on hNa~v~1.7hNa~v~1.7Q10RIEMN-terminusQ10hNa~v~1.7I62VFEBN-terminusI62hNa~v~1.7I136VIEMDI S1I136hNa~v~1.7P149QFEBDI S1-S2P149hNa~v~1.7R185HPEPDDI S3R185hNa~v~1.7R185HSFNDI S3R185hNa~v~1.7S211PIEMDI S3-S4S211hNa~v~1.7F216SIEMDI S4F216hNa~v~1.7I228MDSDI S4I228hNa~v~1.7I228MSFNDI S4I228hNa~v~1.7I234TIEMDI S5I234hNa~v~1.7S241TIEMDI S5S241hNa~v~1.7L245VIEMDI S5L245hNa~v~1.7N395KIEMDI S6N395hNa~v~1.7V400MIEMDI S6V400hNa~v~1.7E406KIEMDI S6E406hNa~v~1.7S490NFEBDI - DIIS490hNa~v~1.7E519KDSDI - DIIE519hNa~v~1.7P610TIEMDI - DIIP610hNa~v~1.7G616RIEMDI - DIIG616hNa~v~1.7D623NSFNDI - DIID623hNa~v~1.7N641YFEBDI - DIIN641hNa~v~1.7K666RFEBDI - DIIK666hNa~v~1.7K666RDSDI - DIIK666hNa~v~1.7I695MDSDI - DIII695hNa~v~1.7C710YDSDI - DIIC710hNa~v~1.7I731KSFNDI - DIII731hNa~v~1.7I750VSFNDII S1I750hNa~v~1.7I750VDSDII S1I750hNa~v~1.7I750VFEBDII S1I750hNa~v~1.7L834RIEMDII S4L834hNa~v~1.7I859TIEMDII S5I859hNa~v~1.7G867DIEMDII S5G867hNa~v~1.7L869FIEMDII S5L869hNa~v~1.7L869HIEMDII S5L869hNa~v~1.7A874PIEMDII S5A874hNa~v~1.7V883GIEMDII S5V883hNa~v~1.7Q886EIEMDII S5Q886hNa~v~1.7R907QCIPDII S5-S6R907hNa~v~1.7M943LSFNDII S5-S6M943hNa~v~1.7V1002LSFNDII - DIIIV1002hNa~v~1.7R1007CPEPDDII - DIIIR1007hNa~v~1.7L1134FDSDII - DIIIL1134hNa~v~1.7E1171QDSDII - DIIIE1171hNa~v~1.7A1247ECIPDIII S2A1247hNa~v~1.7L1278VDSDIII S3-S4L1278hNa~v~1.7V1309DPEPDDIII S4-S5V1309hNa~v~1.7V1309FPEPDDIII S4-S5V1309hNa~v~1.7V1310FPEPDDIII S4-S5V1310hNa~v~1.7P1319LIEMDIII S4-S5P1319hNa~v~1.7F1460VIEMDIII S6F1460hNa~v~1.7I1472TPEPDDIII - DIVI1472hNa~v~1.7F1473VPEPDDIII - DIVF1473hNa~v~1.7T1475IPEPDDIII - DIVT1475hNa~v~1.7M1543ISFNDIV S2M1543hNa~v~1.7G1618RPEPDDIV S4G1618hNa~v~1.7L1623PPEPDDIV S4L1623hNa~v~1.7M1638KPEPDDIV S5M1638hNa~v~1.7A1643EPEPDDIV S5A1643hNa~v~1.7A1643EIEMDIV S5A1643hNa~v~1.7A1643GIEMDIV S5A1643hNa~v~1.7A1643TIEMDIV S5A1643hNa~v~1.7W1786RCIPC-terminusW1786IEM: Primary erythermalgia; PEPD: Paroxysmal extreme pain disorder; CIP: Indifference to pain, congenital, autosomal recessive; DS: Dravet syndrome; SFN: Small fiber neuropathy; FEB: Febrile seizures Table 2Structural mapping of disease-related mutations identified in human Na~v~1.1Related proteinsMutationsDiseasesStructural positionMap on hNa~v~1.7hNa~v~1.1R27TGEFS+2N-terminusQ25hNa~v~1.1S74PGEFS+2N-terminusS72hNa~v~1.1D188VGEFS+2DI S3D186hNa~v~1.1F218LGEFS+2DI S4F216hNa~v~1.1T254IGEFS+2DI S5T252hNa~v~1.1S291GGEFS+2DI S5-S6S279hNa~v~1.1R377QGEFS+2DI S5-S6R356hNa~v~1.1Y388HGEFS+2DI S5-S6Y367hNa~v~1.1Y790CGEFS+2DII S1-S2H766hNa~v~1.1R859CGEFS+2DII S4R835hNa~v~1.1R859HGEFS+2DII S4R835hNa~v~1.1T875MGEFS+2DII S4-S5T851hNa~v~1.1I899TGEFS+2DII S5I875hNa~v~1.1N935HGEFS+2DII S5-S6N911hNa~v~1.1R946HGEFS+2DII S5-S6R922hNa~v~1.1M960TGEFS+2DII S5-S6M936hNa~v~1.1M973VGEFS+2DII S6M949hNa~v~1.1M976IGEFS+2DII S6M952hNa~v~1.1I978MGEFS+2DII S6I954hNa~v~1.1W1204RGEFS+2DII - DIIIW1178hNa~v~1.1W1204SGEFS+2DII - DIIIW1178hNa~v~1.1L1230FGEFS+2DIII S1L1204hNa~v~1.1K1249NGEFS+2DIII S2K1223hNa~v~1.1T1250MGEFS+2DIII S2I1224hNa~v~1.1K1270TGEFS+2DIII S2K1244hNa~v~1.1L1309FGEFS+2DIII S3-S4L1283hNa~v~1.1V1353LGEFS+2DIII S5V1327hNa~v~1.1V1366IGEFS+2DIII S5V1340hNa~v~1.1N1414DGEFS+2DIII S5-S6N1388hNa~v~1.1V1428AGEFS+2DIII S5-S6V1402hNa~v~1.1R1596HGEFS+2DIV S2-S3R1570hNa~v~1.1R1648HGEFS+2DIV S4R1622hNa~v~1.1I1656MGEFS+2DIV S5I1630hNa~v~1.1R1657CGEFS+2DIV S5R1631hNa~v~1.1A1685VGEFS+2DIV S5A1659hNa~v~1.1F1687SGEFS+2DIV S5F1661hNa~v~1.1P1739LGEFS+2DIV S5-S6P1713hNa~v~1.1D1742GGEFS+2DIV S5-S6D1716hNa~v~1.1F1765LGEFS+2DIV S6Y1739hNa~v~1.1E1795KGEFS+2C-terminusE1769hNa~v~1.1M1852TGEFS+2C-terminusM1826hNa~v~1.1V1857LGEFS+2C-terminusV1831hNa~v~1.1D1866YGEFS+2C-terminusD1840hNa~v~1.1I1867TGEFS+2C-terminusI1841hNa~v~1.1G58VEIEE6N-terminusG56hNa~v~1.1L61FEIEE6N-terminusL59hNa~v~1.1F63LEIEE6N-terminusF61hNa~v~1.1I68TEIEE6N-terminusI66hNa~v~1.1E78DEIEE6N-terminusE76hNa~v~1.1D79HEIEE6N-terminusD77hNa~v~1.1D79NEIEE6N-terminusD77hNa~v~1.1Y84CEIEE6N-terminusY82hNa~v~1.1F90SEIEE6N-terminusF88hNa~v~1.1I91TEIEE6N-terminusI89hNa~v~1.1A98PEIEE6N-terminusT96hNa~v~1.1R101QEIEE6N-terminusR99hNa~v~1.1R101WEIEE6N-terminusR99hNa~v~1.1S103GEIEE6N-terminusN101hNa~v~1.1T105IEIEE6N-terminusT103hNa~v~1.1L108REIEE6N-terminusL106hNa~v~1.1T112IEIEE6N-terminusS110hNa~v~1.1R118SEIEE6N-terminusR116hNa~v~1.1I124NEIEE6N-terminusI122hNa~v~1.1H127DEIEE6N-terminusH125hNa~v~1.1T162PEIEE6DI S2T160hNa~v~1.1I171KEIEE6DI S2V169hNa~v~1.1I171REIEE6DI S2V169hNa~v~1.1A175TEIEE6DI S2-23A173hNa~v~1.1A175VEIEE6DI S2-S3A173hNa~v~1.1G177EEIEE6DI S2-S3G175hNa~v~1.1C179REIEE6DI S2-S3C177hNa~v~1.1W190REIEE6DI S3W188hNa~v~1.1N191KEIEE6DI S3N189hNa~v~1.1N191YEIEE6DI S3N189hNa~v~1.1D194GEIEE6DI S3D192hNa~v~1.1D194NEIEE6DI S3D192hNa~v~1.1T199REIEE6DI S3V197hNa~v~1.1T217KEIEE6DI S3-S4T215hNa~v~1.1A223EEIEE6DI S4A221hNa~v~1.1T226MEIEE6DI S4T224hNa~v~1.1T226REIEE6DI S4T224hNa~v~1.1I227SEIEE6DI S4I225hNa~v~1.1I227TEIEE6DI S4I225hNa~v~1.1G232SEIEE6DI S4-S5G230hNa~v~1.1L233REIEE6DI S5L231hNa~v~1.1A239TEIEE6DI S5A237hNa~v~1.1A239VEIEE6DI S5A237hNa~v~1.1S243YEIEE6DI S5S241hNa~v~1.1I252NEIEE6DI S5I250hNa~v~1.1S259REIEE6DI S5S257hNa~v~1.1G265WEIEE6DI S5G263hNa~v~1.1C277REIEE6DI S5-S6C275hNa~v~1.1W280CEIEE6DI S5-S6N278hNa~v~1.1W280REIEE6DI S5-S6N278hNa~v~1.1P281AEIEE6DI S5-S6S279hNa~v~1.1P281LEIEE6DI S5-S6S279hNa~v~1.1P281SEIEE6DI S5-S6S279hNa~v~1.1E289VEIEE6DI S5-S6E287hNa~v~1.1T297IEIEE6DI S5-S6--hNa~v~1.1R322IEIEE6DI S5-S6R301hNa~v~1.1S340FEIEE6DI S5-S6T319hNa~v~1.1A342VEIEE6DI S5-S6S321hNa~v~1.1G343DEIEE6DI S5-S6G322hNa~v~1.1C345REIEE6DI S5-S6C324hNa~v~1.1C351WEIEE6DI S5-S6C330hNa~v~1.1G355DEIEE6DI S5-S6G334hNa~v~1.1R356GEIEE6DI S5-S6R335hNa~v~1.1N357IEIEE6DI S5-S6N336hNa~v~1.1P358TEIEE6DI S5-S6P357hNa~v~1.1N359SEIEE6DI S5-S6D338hNa~v~1.1T363PEIEE6DI S5-S6T342hNa~v~1.1T363REIEE6DI S5-S6T342hNa~v~1.1D366EEIEE6DI S5-S6D345hNa~v~1.1L378QEIEE6DI S5-S6L357hNa~v~1.1M379REIEE6DI S5-S6M358hNa~v~1.1F383LEIEE6DI S5-S6Y362hNa~v~1.1W384REIEE6DI S5-S6M363hNa~v~1.1R393CEIEE6DI S5-S6R372hNa~v~1.1R393HEIEE6DI S5-S6R372hNa~v~1.1R393SEIEE6DI S5-S6R372hNa~v~1.1M400VEIEE6DI S5-S6M379hNa~v~1.1F403LEIEE6DI S6F383hNa~v~1.1F403VEIEE6DI S6F382hNa~v~1.1V406FEIEE6DI S6V385hNa~v~1.1L409WEIEE6DI S6L388hNa~v~1.1Y413NEIEE6DI S6Y392hNa~v~1.1Y426CEIEE6DI S6Y405hNa~v~1.1Y426NEIEE6DI S6Y405hNa~v~1.1S525FEIEE6DI - DIIS505hNa~v~1.1S626GEIEE6DI - DIIS606hNa~v~1.1D674GEIEE6DI - DIID651hNa~v~1.1N762DEIEE6DI - DIIY738hNa~v~1.1L783PEIEE6DII S1L759hNa~v~1.1M785TEIEE6DII S1-S2M761hNa~v~1.1T812IEIEE6DII S2A788hNa~v~1.1T812REIEE6DII S2A788hNa~v~1.1L842REIEE6DII S3L818hNa~v~1.1S843REIEE6DII S3S819hNa~v~1.1E846KEIEE6DII S3E822hNa~v~1.1R859CEIEE6DII S4R835hNa~v~1.1R862QEIEE6DII S4R838hNa~v~1.1R865GEIEE6DII S4R841hNa~v~1.1T875KEIEE6DII S4-S5T851hNa~v~1.1T875MEIEE6DII S4-S5T851hNa~v~1.1L876IEIEE6DII S5L852hNa~v~1.1L890PEIEE6DII S5L866hNa~v~1.1V896FEIEE6DII S5V872hNa~v~1.1V896LEIEE6DII S5V872hNa~v~1.1F902CEIEE6DII S5F878hNa~v~1.1C927FEIEE6DII S5-S6C903hNa~v~1.1R931CEIEE6DII S5-S6R907hNa~v~1.1W932CEIEE6DII S5-S6W908hNa~v~1.1H933PEIEE6DII S5-S6H909hNa~v~1.1M934IEIEE6DII S5-S6M910hNa~v~1.1H939PEIEE6DII S5-S6H915hNa~v~1.1H939QEIEE6DII S5-S6H915hNa~v~1.1H939YEIEE6DII S5-S6H915hNa~v~1.1S940FEIEE6DII S5-S6S916hNa~v~1.1L942PEIEE6DII S5-S6L918hNa~v~1.1I943NEIEE6DII S5-S6I919hNa~v~1.1V944AEIEE6DII S5-S6V920hNa~v~1.1V944EEIEE6DII S5-S6V920hNa~v~1.1F945LEIEE6DII S5-S6F921hNa~v~1.1R946CEIEE6DII S5-S6R922hNa~v~1.1R946HEIEE6DII S5-S6R922hNa~v~1.1R946SEIEE6DII S5-S6R922hNa~v~1.1C949SEIEE6DII S5-S6C925hNa~v~1.1C949YEIEE6DII S5-S6C925hNa~v~1.1G950EEIEE6DII S5-S6G926hNa~v~1.1G950REIEE6DII S5-S6G926hNa~v~1.1W952GEIEE6DII S5-S6W928hNa~v~1.1E954KEIEE6DII S5-S6E930hNa~v~1.1M956KEIEE6DII S5-S6M932hNa~v~1.1W957LEIEE6DII S5-S6W933hNa~v~1.1C959REIEE6DII S5-S6C935hNa~v~1.1M960VEIEE6DII S5-S6M936hNa~v~1.1M973KEIEE6DII S6M949hNa~v~1.1M976IEIEE6DII S6M952hNa~v~1.1G979VEIEE6DII S6G955hNa~v~1.1N985IEIEE6DII S6N961hNa~v~1.1L986FEIEE6DII S6L962hNa~v~1.1L986PEIEE6DII S6L962hNa~v~1.1F987LEIEE6DII S6F963hNa~v~1.1S993REIEE6DII - DIIIS969hNa~v~1.1D998GEIEE6DII - DIIID974hNa~v~1.1E1068KEIEE6DII - DIIIE1045hNa~v~1.1L1207PEIEE6DII - DIIII1181hNa~v~1.1R1208KEIEE6DII - DIIIR1182hNa~v~1.1T1210KEIEE6DII - DIIIT1184hNa~v~1.1E1221KEIEE6DIII S1E1195hNa~v~1.1L1230FEIEE6DIII S1L1204hNa~v~1.1S1231REIEE6DIII S1S1205hNa~v~1.1S1231TEIEE6DIII S1S1205hNa~v~1.1G1233REIEE6DIII S1G1207hNa~v~1.1E1238DEIEE6DIII S1-S2E1212hNa~v~1.1D1239GEIEE6DIII S1-S2D1213hNa~v~1.1D1239YEIEE6DIII S1-S2D1213hNa~v~1.1R1245QEIEE6DIII S1-S2K1219hNa~v~1.1A1255DEIEE6DIII S2A1229hNa~v~1.1T1260PEIEE6DIII S2T1234hNa~v~1.1F1263LEIEE6DIII S2F1237hNa~v~1.1L1265PEIEE6DIII S2L1239hNa~v~1.1E1266AEIEE6DIII S2E1240hNa~v~1.1G1275VEIEE6DIII S2-S3G1249hNa~v~1.1W1284SEIEE6DIII S3W1258hNa~v~1.1L1287PEIEE6DIII S3L1261hNa~v~1.1D1288NEIEE6DIII S3D1262hNa~v~1.1R1316GEIEE6DIII S4R1290hNa~v~1.1R1316SEIEE6DIII S4R1290hNa~v~1.1A1320VEIEE6DIII S4A1294hNa~v~1.1A1326PEIEE6DIII S4A1300hNa~v~1.1S1328PEIEE6DIII S4-S5S1302hNa~v~1.1V1335MEIEE6DIII S4-S5V1309hNa~v~1.1A1339VEIEE6DIII S4-S5A1313hNa~v~1.1I1344MEIEE6DIII S4-S5I1318hNa~v~1.1V1350GEIEE6DIII S5V1324hNa~v~1.1L1355PEIEE6DIII S5L1329hNa~v~1.1W1358REIEE6DIII S5W1332hNa~v~1.1W1358SEIEE6DIII S5W1332hNa~v~1.1N1367KEIEE6DIII S5N1341hNa~v~1.1A1370PEIEE6DIII S5-S6A1344hNa~v~1.1N1378HEIEE6DIII S5-S6N1352hNa~v~1.1N1378TEIEE6DIII S5-S6N1352hNa~v~1.1F1385VEIEE6DIII S5-S6F1359hNa~v~1.1V1390MEIEE6DIII S5-S6V1364hNa~v~1.1N1391SEIEE6DIII S5-S6P1365hNa~v~1.1H1393PEIEE6DIII S5-S6R1367hNa~v~1.1T1394IEIEE6DIII S5-S6S1368hNa~v~1.1C1396GEIEE6DIII S5-S6C1370hNa~v~1.1C1396YEIEE6DIII S5-S6C1370hNa~v~1.1N1414YEIEE6DIII S5-S6N1388hNa~v~1.1D1416GEIEE6DIII S5-S6D1390hNa~v~1.1N1417SEIEE6DIII S5-S6N1391hNa~v~1.1V1418GEIEE6DIII S5-S6V1392hNa~v~1.1Y1422CEIEE6DIII S5-S6Y1396hNa~v~1.1L1423FEIEE6DIII S5-S6L1397hNa~v~1.1L1426REIEE6DIII S5-S6L1400hNa~v~1.1Q1427PEIEE6DIII S5-S6Q1401hNa~v~1.1F1431IEIEE6DIII S5-S6F1405hNa~v~1.1G1433EEIEE6DIII S5-S6G1407hNa~v~1.1G1433REIEE6DIII S5-S6G1407hNa~v~1.1G1433VEIEE6DIII S5-S6G1407hNa~v~1.1W1434REIEE6DIII S5-S6W1408hNa~v~1.1I1437MEIEE6DIII S5-S6I1411hNa~v~1.1A1441PEIEE6DIII S5-S6A1415hNa~v~1.1Q1450KEIEE6DIII S5-S6Q1424hNa~v~1.1Q1450REIEE6DIII S5-S6Q1424hNa~v~1.1P1451LEIEE6DIII S5-S6P1425hNa~v~1.1P1451SEIEE6DIII S5-S6P1425hNa~v~1.1Y1453CEIEE6DIII S5-S6Y1427hNa~v~1.1E1454KEIEE6DIII S5-S6E1428hNa~v~1.1L1461IEIEE6DIII S6I1435hNa~v~1.1Y1462CEIEE6DIII S6Y1436hNa~v~1.1Y1462HEIEE6DIII S6Y1436hNa~v~1.1F1463SEIEE6DIII S6F1437hNa~v~1.1G1470WEIEE6DIII S6G1444hNa~v~1.1F1472SEIEE6DIII S6F1446hNa~v~1.1L1475SEIEE6DIII S6L1449hNa~v~1.1N1476KEIEE6DIII S6N1450hNa~v~1.1D1484GEIEE6DIII S6D1458hNa~v~1.1N1485YEIEE6DIII S6N1459hNa~v~1.1E1503KEIEE6DIII - DIVE1477hNa~v~1.1L1514SEIEE6DIII - DIVL1488hNa~v~1.1V1538IEIEE6DIII - DIVV1512hNa~v~1.1D1544AEIEE6DIV S1D1518hNa~v~1.1D1544GEIEE6DIV S1D1518hNa~v~1.1I1545VEIEE6DIV S1I1519hNa~v~1.1M1555REIEE6DIV S1M1529hNa~v~1.1E1561KEIEE6DIV S1-S2E1535hNa~v~1.1V1579EEIEE6DIV S2V1553hNa~v~1.1G1586EEIEE6DIV S2G1560hNa~v~1.1C1588REIEE6DIV S2C1562hNa~v~1.1L1592HEIEE6DIV S2L1566hNa~v~1.1L1592PEIEE6DIV S2L1566hNa~v~1.1R1596CEIEE6DIV S2-S3R1570hNa~v~1.1R1596LEIEE6DIV S2-S3R1570hNa~v~1.1N1605SEIEE6DIV S3N1579hNa~v~1.1D1608GEIEE6DIV S3D1582hNa~v~1.1D1608YEIEE6DIV S3D1582hNa~v~1.1V1612IEIEE6DIV S3V1586hNa~v~1.1V1630LEIEE6DIV S3-S4V1604hNa~v~1.1V1630MEIEE6DIV S3-S4V1604hNa~v~1.1V1637EEIEE6DIV S4V1611hNa~v~1.1I1638NEIEE6DIV S4I1612hNa~v~1.1I1638TEIEE6DIV S4I1612hNa~v~1.1R1639GEIEE6DIV S4R1613hNa~v~1.1R1642SEIEE6DIV S4R1616hNa~v~1.1R1645QEIEE6DIV S4R1619hNa~v~1.1R1648CEIEE6DIV S4R1622hNa~v~1.1R1648HEIEE6DIV S4R1622hNa~v~1.1A1653EEIEE6DIV S4-S5A1627hNa~v~1.1T1658MEIEE6DIV S5T1632hNa~v~1.1T1658REIEE6DIV S5T1632hNa~v~1.1L1660PEIEE6DIV S5L1634hNa~v~1.1F1661SEIEE6DIV S5F1635hNa~v~1.1A1662VEIEE6DIV S5A1636hNa~v~1.1M1664KEIEE6DIV S5M1638hNa~v~1.1L1667PEIEE6DIV S5L1641hNa~v~1.1P1668AEIEE6DIV S5P1642hNa~v~1.1P1668LEIEE6DIV S5P1642hNa~v~1.1N1672IEIEE6DIV S5N1646hNa~v~1.1I1673TEIEE6DIV S5I1647hNa~v~1.1G1674REIEE6DIV S5G1648hNa~v~1.1L1675REIEE6DIV S5L1649hNa~v~1.1L1677FEIEE6DIV S5L1651hNa~v~1.1I1683TEIEE6DIV S5I1657hNa~v~1.1Y1684DEIEE6DIV S5Y1658hNa~v~1.1A1685DEIEE6DIV S5A1659hNa~v~1.1G1688WEIEE6DIV S5G1662hNa~v~1.1F1692SEIEE6DIV S5F1666hNa~v~1.1Y1694CEIEE6DIV S5-S6Y1668hNa~v~1.1F1707VEIEE6DIV S5-S6F1681hNa~v~1.1S1713NEIEE6DIV S5-S6S1687hNa~v~1.1M1714KEIEE6DIV S5-S6M1688hNa~v~1.1M1714REIEE6DIV S5-S6M1688hNa~v~1.1C1716REIEE6DIV S5-S6C1690hNa~v~1.1T1721REIEE6DIV S5-S6T1695hNa~v~1.1G1725CEIEE6DIV S5-S6G1699hNa~v~1.1W1726REIEE6DIV S5-S6W1700hNa~v~1.1D1727GEIEE6DIV S5-S6D1701hNa~v~1.1C1741REIEE6DIV S5-S6C1715hNa~v~1.1G1749EEIEE6DIV S5-S6G1723hNa~v~1.1C1756GEIEE6DIV S5-S6C1730hNa~v~1.1G1762EEIEE6DIV S6G1736hNa~v~1.1I1763NEIEE6DIV S6I1737hNa~v~1.1I1770FEIEE6DIV S6I1744hNa~v~1.1I1770NEIEE6DIV S6I1744hNa~v~1.1I1770TEIEE6DIV S6I1744hNa~v~1.1I1771FEIEE6DIV S6I1745hNa~v~1.1I1771NEIEE6DIV S6I1745hNa~v~1.1S1773FEIEE6DIV S6S1747hNa~v~1.1M1780TEIEE6DIV S6M1754hNa~v~1.1Y1781CEIEE6DIV S6Y1755hNa~v~1.1Y1781HEIEE6DIV S6Y1755hNa~v~1.1I1782MEIEE6DIV S6I1756hNa~v~1.1I1782SEIEE6DIV S6I1756hNa~v~1.1A1783TEIEE6DIV S6A1757hNa~v~1.1A1783VEIEE6DIV S6A1757hNa~v~1.1E1787KEIEE6DIV S6E1761hNa~v~1.1N1788KEIEE6DIV S6N1862hNa~v~1.1A1792TEIEE6C-terminusA1766hNa~v~1.1F1808IEIEE6C-terminusF1782hNa~v~1.1W1812GEIEE6C-terminusW1786hNa~v~1.1W1812SEIEE6C-terminusW1786hNa~v~1.1F1831SEIEE6C-terminusF1805hNa~v~1.1A1832PEIEE6C-terminusA1806hNa~v~1.1L1835FEIEE6C-terminusL1809hNa~v~1.1M1852KEIEE6C-terminusM1826hNa~v~1.1P1855LEIEE6C-terminusP1829hNa~v~1.1G1880EEIEE6C-terminusG1854hNa~v~1.1E1881DEIEE6C-terminusE1855hNa~v~1.1T1909IEIEE6C-terminusT1883hNa~v~1.1I1922TEIEE6C-terminusI1896hNa~v~1.1F90SICEGTCN-terminusF88hNa~v~1.1R101QICEGTCN-terminusR99hNa~v~1.1F178SICEGTCDI S2-S3F176hNa~v~1.1I252MICEGTCDI S5I250hNa~v~1.1H290RICEGTCDI S5-S6S288hNa~v~1.1R393HICEGTCDI S5-S6R372hNa~v~1.1T808SICEGTCDII S2T784hNa~v~1.1V896IICEGTCDII S5V872hNa~v~1.1V944AICEGTCDII S5-S6R920hNa~v~1.1G979RICEGTCDII S6G955hNa~v~1.1V983AICEGTCDII S6V959hNa~v~1.1N1011IICEGTCDII - DIIIN987hNa~v~1.1R1213QICEGTCDII - DIIIK1187hNa~v~1.1Y1254CICEGTCDIII S2Y1228hNa~v~1.1R1325TICEGTCDIII S4R1299hNa~v~1.1S1328PICEGTCDIII S4-S5S1302hNa~v~1.1F1357LICEGTCDIII S5F1331hNa~v~1.1V1366IICEGTCDIII S5V1340hNa~v~1.1C1376RICEGTCDIII S5-S6C1350hNa~v~1.1A1429DICEGTCDIII S5-S6A1403hNa~v~1.1Y1462HICEGTCDIII S6Y1436hNa~v~1.1M1511KICEGTCDIII - DIVM1485hNa~v~1.1V1611FICEGTCDIV S3V1585hNa~v~1.1M1619VICEGTCDIV S3M1593hNa~v~1.1P1632SICEGTCDIV S3-S4P1606hNa~v~1.1Y1684SICEGTCDIV S5Y1658hNa~v~1.1T1709IICEGTCDIV S5-S6T1683hNa~v~1.1A1724PICEGTCDIV S5-S6A1698hNa~v~1.1Y1781CICEGTCDIV S6Y1755hNa~v~1.1F1808LICEGTCC-terminusF1782hNa~v~1.1R1861WICEGTCC-terminusR1835hNa~v~1.1T1174SFHM3DII - DIIIS1148hNa~v~1.1Q1489HFHM3DIII S6Q1463hNa~v~1.1Q1489KFHM3DIII S6Q1463hNa~v~1.1F1499LFHM3DIII - DIVF1473hNa~v~1.1L1649QFHM3DIV S4L1623hNa~v~1.1M145TFEB3ADI S1M143hNa~v~1.1E1308DFEB3ADIII S3-S4D1282GEFS+2: Generalized epilepsy with febrile seizures plus 2; EIEE6: Epileptic encephalopathy, early infantile, 6; ICEGTC: Intractable childhood epilepsy with generalized tonic-clonic seizures; FHM3: Migraine, familial hemiplegic, 3; FEB3A: Febrile seizures, familial, 3A Table 3Structural mapping of disease-related mutations identified in human Na~v~1.2Related proteinsMutationsDiseasesStructural positionMap on hNa~v~1.7hNa~v~1.2E169GEIEE11DI S2E166hNa~v~1.2R188WBFIS3DI S3R185hNa~v~1.2V208EBFIS3DI S3-S4V205hNa~v~1.2N212DEIEE11DI S3-S4N209hNa~v~1.2V213DEIEE11DI S3-S4V210hNa~v~1.2R223QBFIS3DI S4R220hNa~v~1.2T236SEIEE11DI S5T233hNa~v~1.2M252VBFIS3DI S5M249hNa~v~1.2V261MBFIS3DI S5V258hNa~v~1.2A263TEIEE11DI S5A260hNa~v~1.2A263VEIEE11DI S5A260hNa~v~1.2D322NDSDI - DIID298hNa~v~1.2F328VDSDI - DIIY305hNa~v~1.2E430QBFIS3DI - DIIE407hNa~v~1.2D649NDSDI - DIID623hNa~v~1.2R853QEIEE11DII S4R838hNa~v~1.2N876TEIEE11DII S5N861hNa~v~1.2V892IBFIS3DII S5V877hNa~v~1.2E999KEIEE11DII - DIIID984hNa~v~1.2N1001KBFIS3DII - DIIIN986hNa~v~1.2L1003IBFIS3DII - DIIIL988hNa~v~1.2E1211KEIEE11DIII S1E1195hNa~v~1.2R1312TEIEE11DIII S4R1296hNa~v~1.2R1312TDSDIII S4R1296hNa~v~1.2R1319QBFIS3DIII S4-S5R1303hNa~v~1.2M1323VEIEE11DIII S4-S5M1307hNa~v~1.2V1326LEIEE11DIII S4-S5V1310hNa~v~1.2V1326DEIEE11DIII S4-S5V1310hNa~v~1.2L1330FBFIS3DIII S4-S5L1314hNa~v~1.2S1336YEIEE11DIII S4-S5S1320hNa~v~1.2M1338TEIEE11DIII S5M1322hNa~v~1.2L1342PBFIS3DIII S5L1326hNa~v~1.2I1473MEIEE11DIII S6I1457hNa~v~1.2L1563VBFIS3DIV S2L1547hNa~v~1.2Y1589CBFIS3DIV S2-S3Y1573hNa~v~1.2I1596SBFIS3DIV S3I1580hNa~v~1.2T1623NEIEE11DIV S3-S4T1607hNa~v~1.2R1629LEIEE11DIV S4R1613hNa~v~1.2L1660YEIEE11DIV S5L1644hNa~v~1.2R1918HBFIS3C-terminusR1902BFIS3: Seizures, benign familial infantile 3; EIEE11: Epileptic encephalopathy, early infantile, 11; DS: Dravet syndrome Table 4Structural mapping of disease-related mutations identified in human Na~v~1.3Related proteinsMutationsDiseasesStructural positionMap on hNa~v~1.7hNa~v~1.3K354QCPEDI - DIIK332hNa~v~1.3R357QCPEDI - DIIR335hNa~v~1.3D815NCPEDII S2-S3D799hNa~v~1.3E1160KCPEDII - DIIIM1146hNa~v~1.3M1372VCPEDIII S5-S6R1358hNa~v~1.3G1862CCPEC-terminusG1851CPE: Cryptogenic partial epilepsy Table 5Structural mapping of disease-related mutations identified in human Na~v~1.4Related proteinsMutationsDiseasesStructural positionMap on hNa~v~1.7hNa~v~1.4Q270KPMCDI S5Q265hNa~v~1.4I693TPMCDII S5I858hNa~v~1.4T704MPMCDII S5T870hNa~v~1.4S804FPMCDII - DIIIS970hNa~v~1.4A1152DPMCDIII S4-S5A1313hNa~v~1.4A1156TPMCDIII S4-S5A1317hNa~v~1.4V1293IPMCDIII S6V1455hNa~v~1.4G1306APMCDIII S6G1468hNa~v~1.4G1306EPMCDIII S6G1468hNa~v~1.4G1306VPMCDIII S6G1468hNa~v~1.4T1313MPMCDIII - DIVT1475hNa~v~1.4L1433RPMCDIV S3L1595hNa~v~1.4L1436PPMCDIV S3L1598hNa~v~1.4R1448CPMCDIV S4R1610hNa~v~1.4R1448HPMCDIV S4R1610hNa~v~1.4R1448LPMCDIV S4R1610hNa~v~1.4G1456EPMCDIV S4G1618hNa~v~1.4F1473SPMCDIV S5F1635hNa~v~1.4V1589MPMCDIV S6V1751hNa~v~1.4F1705IPMCC-terminusF1867hNa~v~1.4R222WHOKPP2DI S4E217hNa~v~1.4R669HHOKPP2DII S4R835hNa~v~1.4R672CHOKPP2DII S4R838hNa~v~1.4R672GHOKPP2DII S4R838hNa~v~1.4R672HHOKPP2DII S4R838hNa~v~1.4R672SHOKPP2DII S4R838hNa~v~1.4R1129QHOKPP2DIII S4R1290hNa~v~1.4R1132QHOKPP2DIII S4R1293hNa~v~1.4R1135CHOKPP2DIII S4R1296hNa~v~1.4R1135HHOKPP2DIII S4R1299hNa~v~1.4P1158SHOKPP2DIII S4-S5P1319hNa~v~1.4T704MHYPPDII S5T870hNa~v~1.4V781IHYPPDII S6V947hNa~v~1.4A1156THYPPDIII S4-S5A1317hNa~v~1.4L1433RHYPPDIV S3L1595hNa~v~1.4M1592VHYPPDIV S6M1754hNa~v~1.4R675GNKPPDII S4R841hNa~v~1.4R675QNKPPDII S4R841hNa~v~1.4R675WNKPPDII S4R841hNa~v~1.4V781INKPPDII S6V947hNa~v~1.4R1129QNKPPDIII S4R1290hNa~v~1.4M1592VNKPPDIV S6M1754hNa~v~1.4I141VMYOSCN4ADI S1I136hNa~v~1.4R225WMYOSCN4ADI S4R220hNa~v~1.4N440KMYOSCN4ADI S6N395hNa~v~1.4V445MMYOSCN4ADI - DIIV440hNa~v~1.4E452KMYOSCN4ADI - DIIE447hNa~v~1.4I588VMYOSCN4ADII S1I754hNa~v~1.4F671SMYOSCN4ADII S4F837hNa~v~1.4A715TMYOSCN4ADII S5A881hNa~v~1.4S804NMYOSCN4ADII - DIIIS970hNa~v~1.4A1156TMYOSCN4ADIII S4-S5A1317hNa~v~1.4P1158LMYOSCN4ADIII S4-S5P1319hNa~v~1.4I1160VMYOSCN4ADIII S4-S5I1321hNa~v~1.4N1297KMYOSCN4ADIII S6I1457hNa~v~1.4G1306EMYOSCN4ADIII S6G1468hNa~v~1.4G1306VMYOSCN4ADIII S6G1468hNa~v~1.4I1310NMYOSCN4ADIII - DIVI1472hNa~v~1.4M1476IMYOSCN4ADIV S5M1638hNa~v~1.4A1481DMYOSCN4ADIV S5A1643hNa~v~1.4Q1633EMYOSCN4AC-terminusQ1795hNa~v~1.4R104HCMS16N-terminusR99hNa~v~1.4M203KCMS16DI S3F198hNa~v~1.4R225WCMS16DI S4R220hNa~v~1.4S246LCMS16DI S5S241hNa~v~1.4P382TCMS16DI S5-S6P337hNa~v~1.4D1069NCMS16DIII S2D1230hNa~v~1.4R1135CCMS16DIII S4-S5R1299hNa~v~1.4C1209FCMS16DIII S5-S6C1370hNa~v~1.4V1442ECMS16DIV S3-S4V1604hNa~v~1.4R1454WCMS16DIV S4R1616hNa~v~1.4R1457HCMS16DIV S4R1619PMC: Paramyotonia congenita of von Eulenburg; HOKPP2: Periodic paralysis hypokalemic 2; HYPP: Periodic paralysis hyperkalemic; NKPP: Periodic paralysis normokalemic; MYOSCN4A: Myotonia SCN4A-related; CMS16: Myasthenic syndrome, congenital, 16 Table 6Structural mapping of disease-related mutations identified in human Na~v~1.5Related proteinsMutationsDiseasesStructural positionMap on hNa~v~1.7hNa~v~1.5E161KPFHB1ADI S2E156hNa~v~1.5R225WPFHB1ADI S4R220hNa~v~1.5G298SPFHB1ADI S4-S5--hNa~v~1.5T512IPFHB1ADI - DIIV518hNa~v~1.5G514CPFHB1ADI - DIIG520hNa~v~1.5G752RPFHB1ADII S2-S3G779hNa~v~1.5R1232WPFHB1ADIII S1-S2K1219hNa~v~1.5D1275NPFHB1ADIII S3D1262hNa~v~1.5D1595NPFHB1ADIII D3-S4D1582hNa~v~1.5T1620KPFHB1ADIV S3-S4T1607hNa~v~1.5G9VLQT3N-terminusG8hNa~v~1.5R18QLQT3N-terminusK17hNa~v~1.5R27HLQT3N-terminusR26hNa~v~1.5E30GLQT3N-terminusE29hNa~v~1.5R43QLQT3N-terminusK40hNa~v~1.5E48KLQT3N-terminusD43hNa~v~1.5P52SLQT3N-terminusP47hNa~v~1.5R53QLQT3N-terminusK48hNa~v~1.5R104GLQT3N-terminusR99hNa~v~1.5S115GLQT3N-terminusS110hNa~v~1.5V125LLQT3N-terminusI125hNa~v~1.5L212PLQT3DI S3-S4L207hNa~v~1.5R222QLQT3DI S4R217hNa~v~1.5R225QLQT3DI S4R220hNa~v~1.5R225WLQT3DI S4R220hNa~v~1.5V240MLQT3DI S5V235hNa~v~1.5Q245KLQT3DI S5Q240hNa~v~1.5V247LLQT3DI S5L242hNa~v~1.5N275KLQT3DI S5-S6N270hNa~v~1.5G289SLQT3DI S5-S6E284hNa~v~1.5R340WLQT3DI S5-S6T329hNa~v~1.5R367CLQT3DI S5-S6R356hNa~v~1.5T370MLQT3DI S5-S6T359hNa~v~1.5I397TLQT3DI S6I386hNa~v~1.5L404QLQT3DI S6L393hNa~v~1.5N406KLQT3DI S6N395hNa~v~1.5L409VLQT3DI S6L398hNa~v~1.5V411MLQT3DI S6V400hNa~v~1.5A413ELQT3DI S6A402hNa~v~1.5A413TLQT3DI S6A402hNa~v~1.5E462ALQT3DI - DIIE464hNa~v~1.5E462KLQT3DI - DIIE464hNa~v~1.5F530VLQT3DI - DIIF555hNa~v~1.5R535QLQT3DI - DIIR562hNa~v~1.5R569WLQT3DI - DIIE596hNa~v~1.5S571ILQT3DI - DIIR598hNa~v~1.5A572DLQT3DI - DIIS599hNa~v~1.5A572SLQT3DI - DIIS599hNa~v~1.5A572VLQT3DI - DIIS599hNa~v~1.5Q573ELQT3DI - DIIS600hNa~v~1.5G579RLQT3DI - DIIS606hNa~v~1.5G615ELQT3DI - DIIN641hNa~v~1.5L619FLQT3DI - DIIL615hNa~v~1.5P637LLQT3DI - DII--hNa~v~1.5G639RLQT3DI - DIIK666hNa~v~1.5P648LLQT3DI - DIIL675hNa~v~1.5E654KLQT3DI - DIIN681hNa~v~1.5L673PLQT3DI - DIIV700hNa~v~1.5R680HLQT3DI - DIIQ708hNa~v~1.5R689CLQT3DI - DIIR716hNa~v~1.5R689HLQT3DI - DIIR716hNa~v~1.5P701LLQT3DI - DIIP728hNa~v~1.5T731ILQT3DII S1T758hNa~v~1.5Q750RLQT3DII S2A777hNa~v~1.5D772NLQT3DII S2-S3D799hNa~v~1.5F816YLQT3DII S4F843hNa~v~1.5I848FLQT3DII S5I875hNa~v~1.5S941NLQT3DII - DIIIS970hNa~v~1.5Q960KLQT3DII - DIIIQ989hNa~v~1.5R965LLQT3DII - DIIIR994hNa~v~1.5R971CLQT3DII - DIIIN1000hNa~v~1.5C981FLQT3DII - DIII--hNa~v~1.5A997SLQT3DII - DIIIE1023hNa~v~1.5C1004RLQT3DII - DIIIY1037hNa~v~1.5E1053KLQT3DII - DIIIE1095hNa~v~1.5T1069MLQT3DII - DIIID1111hNa~v~1.5A1100VLQT3DII - DIII--hNa~v~1.5D1114NLQT3DII - DIII--hNa~v~1.5D1166NLQT3DII - DIIIA1153hNa~v~1.5R1193QLQT3DII - DIIIN1180hNa~v~1.5Y1199SLQT3DII - DIIIY1186hNa~v~1.5E1225KLQT3DIII S1-S2E1212hNa~v~1.5E1231KLQT3DIII S1-S2R1218hNa~v~1.5F1250LLQT3DIII S2F1237hNa~v~1.5L1283MLQT3DIII S3L1270hNa~v~1.5E1295KLQT3DIII S3-S4D1282hNa~v~1.5T1304MLQT3DIII S4T1291hNa~v~1.5N1325SLQT3DIII S4-S5N1312hNa~v~1.5A1326SLQT3DIII S4-S5A1313hNa~v~1.5A1330PLQT3DIII S4-S5A1317hNa~v~1.5A1330TLQT3DIII S4-S5A1317hNa~v~1.5P1332LLQT3DIII S4-S5P1319hNa~v~1.5S1333YLQT3DIII S4-S5S1320hNa~v~1.5I1334VLQT3DIII S4-S5I1321hNa~v~1.5L1338VLQT3DIII S5L1325hNa~v~1.5R1432SLQT3DIII S5-S6V1419hNa~v~1.5S1458YLQT3DIII S6S1445hNa~v~1.5N1472SLQT3DIII S6N1459hNa~v~1.5F1473CLQT3DIII S6F1460hNa~v~1.5G1481ELQT3DIII - DIVG1468hNa~v~1.5F1486LLQT3DIII - DIVF1473hNa~v~1.5M1487LLQT3DIII - DIVM1474hNa~v~1.5T1488RLQT3DIII - DIVT1475hNa~v~1.5E1489DLQT3DIII - DIVE1476hNa~v~1.5K1493RLQT3DIII - DIVK1480hNa~v~1.5Y1495SLQT3DIII - DIVY1482hNa~v~1.5M1498VLQT3DIII - DIVM1485hNa~v~1.5L1501VLQT3DIII - DIVL1488hNa~v~1.5K1505NLQT3DIII - DIVK1492hNa~v~1.5V1532ILQT3DIV S1I1519hNa~v~1.5L1560FLQT3DIV S2L1547hNa~v~1.5I1593MLQT3DIV S3I1580hNa~v~1.5F1594SLQT3DIV S3F1581hNa~v~1.5D1595NLQT3DIV S3D1582hNa~v~1.5F1596ILQT3DIV S3F1583hNa~v~1.5S1609WLQT3DIV S3A1596hNa~v~1.5T1620KLQT3DIV S3-S4T1607hNa~v~1.5R1623LLQT3DIV S4R1610hNa~v~1.5R1623QLQT3DIV S4R1610hNa~v~1.5R1626HLQT3DIV S4R1613hNa~v~1.5R1626PLQT3DIV S4R1613hNa~v~1.5R1644CLQT3DIV S5R1631hNa~v~1.5R1644HLQT3DIV S5R1631hNa~v~1.5T1645MLQT3DIV S5T1632hNa~v~1.5L1650FLQT3DIV S5L1637hNa~v~1.5M1652RLQT3DIV S5M1639hNa~v~1.5M1652TLQT3DIV S5M1639hNa~v~1.5I1660VLQT3DIV S5I1647hNa~v~1.5V1667ILQT3DIV S5V1654hNa~v~1.5T1723NLQT3DIV S5-S6S1710hNa~v~1.5R1739WLQT3DIV S5-S6E1727hNa~v~1.5L1761FLQT3DIV S6L1749hNa~v~1.5L1761HLQT3DIV S6L1749hNa~v~1.5V1763MLQT3DIV S6V1751hNa~v~1.5M1766LLQT3DIV S6M1754hNa~v~1.5Y1767CLQT3DIV S6Y1755hNa~v~1.5I1768VLQT3DIV S6I1756hNa~v~1.5V1777MLQT3C-terminusV1765hNa~v~1.5T1779MLQT3C-terminusT1767hNa~v~1.5E1784KLQT3C-terminusE1772hNa~v~1.5D1790GLQT3C-terminusD1778hNa~v~1.5Y1795CLQT3C-terminusY1783hNa~v~1.5Y1795YDLQT3C-terminusY1783hNa~v~1.5D1819NLQT3C-terminusA1807hNa~v~1.5L1825PLQT3C-terminusL1813hNa~v~1.5R1826HLQT3C-terminusL1814hNa~v~1.5D1839GLQT3C-terminusD1827hNa~v~1.5R1897WLQT3C-terminusK1885hNa~v~1.5E1901QLQT3C-terminusE1889hNa~v~1.5S1904LLQT3C-terminusS1892hNa~v~1.5Q1909RLQT3C-terminusQ1897hNa~v~1.5R1913HLQT3C-terminusR1901hNa~v~1.5A1949SLQT3C-terminusF1934hNa~v~1.5V1951LLQT3C-terminusN1936hNa~v~1.5Y1977NLQT3C-terminusY1958hNa~v~1.5F2004LLQT3C-terminusD1982hNa~v~1.5F2004VLQT3C-terminusD1982hNa~v~1.5R2012CLQT3C-terminus--hNa~v~1.5R18QBRGDA1N-terminusK17hNa~v~1.5R27HBRGDA1N-terminusR26hNa~v~1.5N70KBRGDA1N-terminusD65hNa~v~1.5D84NBRGDA1N-terminusD79hNa~v~1.5F93SBRGDA1N-terminusF88hNa~v~1.5I94SBRGDA1N-terminusI89hNa~v~1.5V95IBRGDA1N-terminusV90hNa~v~1.5R104QBRGDA1N-terminusR99hNa~v~1.5R104WBRGDA1N-terminusR99hNa~v~1.5N109KBRGDA1N-terminusP104hNa~v~1.5R121QBRGDA1N-terminusR116hNa~v~1.5R121WBRGDA1N-terminusR116hNa~v~1.5K126EBRGDA1N-terminusK121hNa~v~1.5L136PBRGDA1DI S1L131hNa~v~1.5V146MBRGDA1DI S1I141hNa~v~1.5E161KBRGDA1DI S2E156hNa~v~1.5E161QBRGDA1DI S2E156hNa~v~1.5K175NBRGDA1DI S2K170hNa~v~1.5A178GBRGDA1DI S2-S3A173hNa~v~1.5C182RBRGDA1DI S2-S3C177hNa~v~1.5A185VBRGDA1DI S2-S3E180hNa~v~1.5T187IBRGDA1DI S3T182hNa~v~1.5A204VBRGDA1DI S3A199hNa~v~1.5L212QBRGDA1DI S3-S4L207hNa~v~1.5T220IBRGDA1DI S4T215hNa~v~1.5R222QBRGDA1DI S4R217hNa~v~1.5V223LBRGDA1DI S4V218hNa~v~1.5R225WBRGDA1DI S4R220hNa~v~1.5A226VBRGDA1DI S4A221hNa~v~1.5I230VBRGDA1DI S4T225hNa~v~1.5V232IBRGDA1DI S4V227hNa~v~1.5V240MBRGDA1DI S5V235hNa~v~1.5Q270KBRGDA1DI S5Q265hNa~v~1.5L276QBRGDA1DI S5-S6L271hNa~v~1.5H278DBRGDA1DI S5-S6H273hNa~v~1.5R282CBRGDA1DI S5-S6R277hNa~v~1.5R282HBRGDA1DI S5-S6R277hNa~v~1.5V294MBRGDA1DI S5-S6I289hNa~v~1.5V300IBRGDA1DI S5-S6--hNa~v~1.5L315PBRGDA1DI S5-S6Y304hNa~v~1.5G319SBRGDA1DI S5-S6G308hNa~v~1.5T320NBRGDA1DI S5-S6S319hNa~v~1.5L325RBRGDA1DI S5-S6L314hNa~v~1.5P336LBRGDA1DI S5-S6P325hNa~v~1.5G351DBRGDA1DI S5-S6G340hNa~v~1.5G351VBRGDA1DI S5-S6G340hNa~v~1.5T353IBRGDA1DI S5-S6T342hNa~v~1.5D356NBRGDA1DI S5-S6D345hNa~v~1.5R367CBRGDA1DI S5-S6R356hNa~v~1.5R367HBRGDA1DI S5-S6R356hNa~v~1.5R367LBRGDA1DI S5-S6R356hNa~v~1.5M369KBRGDA1DI S5-S6M358hNa~v~1.5W374GBRGDA1DI S5-S6W363hNa~v~1.5R376HBRGDA1DI S5-S6N365hNa~v~1.5G386EBRGDA1DI S5-S6G375hNa~v~1.5G386RBRGDA1DI S5-S6G375hNa~v~1.5V396ABRGDA1DI S6V385hNa~v~1.5V396LBRGDA1DI S6V385hNa~v~1.5N406SBRGDA1DI S6N395hNa~v~1.5E439KBRGDA1DI - DIID428hNa~v~1.5D501GBRGDA1DI - DIID507hNa~v~1.5G514CBRGDA1DI - DIIG520hNa~v~1.5R526HBRGDA1DI - DIIR540hNa~v~1.5F532CBRGDA1DI - DIIA546hNa~v~1.5F543LBRGDA1DI - DIIF570hNa~v~1.5G552RBRGDA1DI - DIIG579hNa~v~1.5L567QBRGDA1DI - DIIP594hNa~v~1.5G615EBRGDA1DI - DIIN641hNa~v~1.5L619FBRGDA1DI - DIIL615hNa~v~1.5R620CBRGDA1DI - DIIE647hNa~v~1.5T632MBRGDA1DI - DIIG659hNa~v~1.5P640ABRGDA1DI - DIIK667hNa~v~1.5A647DBRGDA1DI - DIIL674hNa~v~1.5P648LBRGDA1DI - DIIL675hNa~v~1.5R661WBRGDA1DI - DIIR688hNa~v~1.5H681PBRGDA1DI - DIIQ708hNa~v~1.5C683GBRGDA1DI - DIIC710hNa~v~1.5P701LBRGDA1DI - DIIP728hNa~v~1.5P717LBRGDA1DI - DIIP744hNa~v~1.5A735EBRGDA1DII S1-S2A762hNa~v~1.5A735VBRGDA1DII S1-S2A762hNa~v~1.5E746KBRGDA1DII S2K773hNa~v~1.5G752RBRGDA1DII S2G779hNa~v~1.5G758EBRGDA1DII S2G785hNa~v~1.5M764RBRGDA1DII S2M791hNa~v~1.5D772NBRGDA1DII S2-S3D799hNa~v~1.5P773SBRGDA1DII S2-S3P800hNa~v~1.5V789IBRGDA1DII S3V816hNa~v~1.5R808PBRGDA1DII S4R835hNa~v~1.5R814QBRGDA1DII S4R841hNa~v~1.5L839PBRGDA1DII S6L866hNa~v~1.5F851LBRGDA1DII S6F878hNa~v~1.5E867QBRGDA1DII S5-S6E894hNa~v~1.5R878CBRGDA1DII S5-S6R907hNa~v~1.5R878HBRGDA1DII S5-S6R907hNa~v~1.5H886PBRGDA1DII S5-S6H915hNa~v~1.5F892IBRGDA1DII S5-S6F921hNa~v~1.5R893CBRGDA1DII S5-S6R922hNa~v~1.5R893HBRGDA1DII S5-S6R922hNa~v~1.5C896SBRGDA1DII S5-S6C925hNa~v~1.5E901KBRGDA1DII S5-S6E930hNa~v~1.5S910LBRGDA1DII S5-S6A939hNa~v~1.5C915RBRGDA1DII S5-S6C944hNa~v~1.5L917RBRGDA1DII S6I946hNa~v~1.5N927SBRGDA1DII S6N956hNa~v~1.5L928PBRGDA1DII S6L957hNa~v~1.5L935PBRGDA1DII S6L964hNa~v~1.5R965CBRGDA1DII - DIIIR994hNa~v~1.5R965HBRGDA1DII - DIIIR994hNa~v~1.5A997TBRGDA1DII - DIIIQ1026hNa~v~1.5R1023HBRGDA1DII - DIIIH1050hNa~v~1.5E1053KBRGDA1DII - DIIIE1095hNa~v~1.5D1055GBRGDA1DII - DIIID1097hNa~v~1.5S1079YBRGDA1DII - DIII--hNa~v~1.5A1113VBRGDA1DII - DIII--hNa~v~1.5S1140TBRGDA1DII - DIIIS1128hNa~v~1.5R1193QBRGDA1DII - DIIIN1180hNa~v~1.5S1219NBRGDA1DIII S1S1206hNa~v~1.5E1225KBRGDA1DIII S1-S2E1212hNa~v~1.5Y1228HBRGDA1DIII S1-S2Y1215hNa~v~1.5R1232QBRGDA1DIII S1-S2K1219hNa~v~1.5R1232WBRGDA1DIII S1-S2K1219hNa~v~1.5K1236NBRGDA1DIII S2K1223hNa~v~1.5L1339PBRGDA1DIII S2L1226hNa~v~1.5E1240QBRGDA1DIII S2E1227hNa~v~1.5D1243NBRGDA1DIII S2D1230hNa~v~1.5V1249DBRGDA1DIII S2I1236hNa~v~1.5E1253GBRGDA1DIII S2E1240hNa~v~1.5G1262SBRGDA1DIII S2-S3G1249hNa~v~1.5W1271CBRGDA1DIII S3W1258hNa~v~1.5D1275NBRGDA1DIII S3D1262hNa~v~1.5A1288GBRGDA1DIII S3-S4A1275hNa~v~1.5F1293SBRGDA1DIII S3-S4Y1280hNa~v~1.5L1311PBRGDA1DIII S4L1298hNa~v~1.5G1319VBRGDA1DIII S4-S5G1306hNa~v~1.5V1323GBRGDA1DIII S4-S5V1310hNa~v~1.5P1332LBRGDA1DIII S4-S5P1319hNa~v~1.5F1344LBRGDA1DIII S5F1331hNa~v~1.5F1344SBRGDA1DIII S5F1331hNa~v~1.5L1346IBRGDA1DIII S5L1333hNa~v~1.5L1346PBRGDA1DIII S5L1333hNa~v~1.5M1351RBRGDA1DIII S5M1338hNa~v~1.5V1353MBRGDA1DIII S5V1340hNa~v~1.5G1358WBRGDA1DIII S5-S6G1345hNa~v~1.5K1359NBRGDA1DIII S5-S6K1346hNa~v~1.5F1360CBRGDA1DIII S5-S6F1347hNa~v~1.5C1363YBRGDA1DIII S5-S6C1350hNa~v~1.5S1382IBRGDA1DIII S5-S6E1369hNa~v~1.5V1405LBRGDA1DIII S5-S6V1392hNa~v~1.5V1405MBRGDA1DIII S5-S6V1392hNa~v~1.5G1406EBRGDA1DIII S5-S6G1393hNa~v~1.5G1406RBRGDA1DIII S5-S6G1393hNa~v~1.5G1408RBRGDA1DIII S5-S6G1395hNa~v~1.5Y1409CBRGDA1DIII S5-S6Y1396hNa~v~1.5L1412FBRGDA1DIII S5-S6L1399hNa~v~1.5K1419EBRGDA1DIII S5-S6K1406hNa~v~1.5G1420RBRGDA1DIII S5-S6G1407hNa~v~1.5A1427SBRGDA1DIII S5-S6A1414hNa~v~1.5A1428VBRGDA1DIII S5-S6A1415hNa~v~1.5R1432GBRGDA1DIII S5-S6V1419hNa~v~1.5R1432SBRGDA1DIII S5-S6V1419hNa~v~1.5G1433VBRGDA1DIII S5-S6N1420hNa~v~1.5P1438LBRGDA1DIII S5-S6P1425hNa~v~1.5E1441QBRGDA1DIII S5-S6E1428hNa~v~1.5I1448LBRGDA1DIII S6I1435hNa~v~1.5I1448TBRGDA1DIII S6I1435hNa~v~1.5Y1449CBRGDA1DIII S6Y1436hNa~v~1.5V1451DBRGDA1DIII S6V1438hNa~v~1.5N1463YBRGDA1DIII S6N1450hNa~v~1.5V1468FBRGDA1DIII S6V1455hNa~v~1.5Y1494NBRGDA1DIII - DIVY1481hNa~v~1.5L1501VBRGDA1DIII - DIVL1488hNa~v~1.5G1502SBRGDA1DIII - DIVG1489hNa~v~1.5R1512WBRGDA1DIII - DIVR1499hNa~v~1.5I1521KBRGDA1DIII - DIVI1508hNa~v~1.5V1525MBRGDA1DIII - DIVV1512hNa~v~1.5K1527RBRGDA1DIII - DIVN1514hNa~v~1.5E1548KBRGDA1DIV S1-S2E1535hNa~v~1.5A1569PBRGDA1DIV S2I1556hNa~v~1.5F1571CBRGDA1DIV S2F1558hNa~v~1.5E1574KBRGDA1DIV S2E1561hNa~v~1.5L1582PBRGDA1DIV S2-S3L1569hNa~v~1.5R1583CBRGDA1DIV S2-S3R1570hNa~v~1.5R1583HBRGDA1DIV S2-S3R1570hNa~v~1.5V1604MBRGDA1DIV S3V1591hNa~v~1.5Q1613LBRGDA1DIV S3-S4E1600hNa~v~1.5T1620MBRGDA1DIV S3-S4T1607hNa~v~1.5R1623QBRGDA1DIV S4R1610hNa~v~1.5R1629QBRGDA1DIV S4R1616hNa~v~1.5G1642EBRGDA1DIV S5G1629hNa~v~1.5R1644CBRGDA1DIV S5R1631hNa~v~1.5A1649VBRGDA1DIV S5A1636hNa~v~1.5I1660VBRGDA1DIV S5I1647hNa~v~1.5G1661RBRGDA1DIV S5G1648hNa~v~1.5V1667IBRGDA1DIV S5V1654hNa~v~1.5S1672YBRGDA1DIV S5A1659hNa~v~1.5A1680TBRGDA1DIV S5-S6A1667hNa~v~1.5A1698TBRGDA1DIV S5-S6G1685hNa~v~1.5T1709MBRGDA1DIV S5-S6T1696hNa~v~1.5T1709RBRGDA1DIV S5-S6T1696hNa~v~1.5G1712SBRGDA1DIV S5-S6G1699hNa~v~1.5D1714GBRGDA1DIV S5-S6D1701hNa~v~1.5N1722DBRGDA1DIV S5-S6N1709hNa~v~1.5C1728RBRGDA1DIV S5-S6C1715hNa~v~1.5C1728WBRGDA1DIV S5-S6C1715hNa~v~1.5G1740RBRGDA1DIV S5-S6G1728hNa~v~1.5G1743EBRGDA1DIV S5-S6G1731hNa~v~1.5G1743RBRGDA1DIV S5-S6G1731hNa~v~1.5V1764FBRGDA1DIV S6V1752hNa~v~1.5T1779MBRGDA1C-terminusT1767hNa~v~1.5E1784KBRGDA1C-terminusE1772hNa~v~1.5Y1795HBRGDA1C-terminusY1783hNa~v~1.5Y1795YDBRGDA1C-terminusY1783hNa~v~1.5Q1832EBRGDA1C-terminusK1820hNa~v~1.5C1850SBRGDA1C-terminusC1838hNa~v~1.5V1861IBRGDA1C-terminusV1849hNa~v~1.5K1872NBRGDA1C-terminusR1860hNa~v~1.5V1903LBRGDA1C-terminusV1891hNa~v~1.5A1924TBRGDA1C-terminusI1912hNa~v~1.5G1935SBRGDA1C-terminusG1920hNa~v~1.5E1938KBRGDA1C-terminusD1923hNa~v~1.5V1951LBRGDA1C-terminusN1936hNa~v~1.5I1968SBRGDA1C-terminusT1949hNa~v~1.5F2004LBRGDA1C-terminusD1982hNa~v~1.5F2004VBRGDA1C-terminusD1982hNa~v~1.5T220ISSS1DI S4T215hNa~v~1.5A735VSSS1DII S1-S2A762hNa~v~1.5P1298LSSS1DIII S3-S4P1285hNa~v~1.5G1408RSSS1DIII S5-S6G1395hNa~v~1.5D1792NSSS1C-terminusE1780hNa~v~1.5S1710LVF1DIV S5-S6S1697hNa~v~1.5F532CSIDSDI - DIIF557hNa~v~1.5S941NSIDSDII - DIIIS970hNa~v~1.5G1084SSIDSDII - DIII--hNa~v~1.5S1333YSIDSDIII S4-S5S1320hNa~v~1.5F1705SSIDSDIV S5-S6F1692hNa~v~1.5D1275NATRST1DIII S3D1262hNa~v~1.5D1275NCMD1EDIII S3D1262hNa~v~1.5M138IATFB10DI S1M133hNa~v~1.5E428KATFB10DI - DIIK417hNa~v~1.5H445DATFB10DI - DIIQ434hNa~v~1.5N470KATFB10DI - DIIS472hNa~v~1.5A572DATFB10DI - DIIS599hNa~v~1.5E655KATFB10DI - DIID682hNa~v~1.5E1053KATFB10DII - DIIIE1095hNa~v~1.5T1131IATFB10DII - DIIIE1140hNa~v~1.5R1826CATFB10C-terminusL1814hNa~v~1.5V1951MATFB10C-terminusN1936hNa~v~1.5N1987KATFB10C-terminusE1967hNa~v~1.5R222QMEPPCDI S4R217PFHB1A: Progressive familial heart block 1A; LQT3: Long QT syndrome 3; BRGDA1: Brugada syndrome 1; SSS1: Sick sinus syndrome 1; VF1: Familial paroxysmal ventricular fibrillation 1; SIDS: Sudden infant death syndrome; ATRST1: Atrial standstill 1; CMD1E: Cardiomyopathy, dilated 1E; ATFB10: Atrial fibrillation, familial, 10; MEPPC: Multifocal ectopic Purkinje-related premature contraction Table 7Structural mapping of disease-related mutations identified in human Na~v~1.6Related proteinsMutationsDiseasesStructural positionMap on hNa~v~1.7hNa~v~1.6D58NEIEE13N-terminusD52hNa~v~1.6F210LEIEE13DI S3-S4F204hNa~v~1.6G214DEIEE13DI S3-S4G208hNa~v~1.6N215REIEE13DI S3-S4N209hNa~v~1.6V216DEIEE13DI S3-S4V210hNa~v~1.6R223GEIEE13DI S4R217hNa~v~1.6F260SEIEE13DI S5F254hNa~v~1.6L407FEIEE13DI S6L398hNa~v~1.6V410LEIEE13DI - DIIV401hNa~v~1.6E479VEIEE13DI - DIIE464hNa~v~1.6R530WEIEE13DI - DIIH515hNa~v~1.6R662CEIEE13DI - DIIQ643hNa~v~1.6T767IEIEE13DII S1T758hNa~v~1.6F846SEIEE13DII S4F837hNa~v~1.6R850QEIEE13DII S4R841hNa~v~1.6L875QEIEE13DII S5L866hNa~v~1.6A890TEIEE13DII S5A881hNa~v~1.6V960DEIEE13DII S6V951hNa~v~1.6N984KEIEE13DII - DIIIN975hNa~v~1.6I1327VEIEE13DIII S4-S5I1321hNa~v~1.6L1331VEIEE13DIII S5L1325hNa~v~1.6G1451SEIEE13DIII S6G1444hNa~v~1.6G1451SEIEE13DIII S6G1444hNa~v~1.6N1466KEIEE13DIII S6N1459hNa~v~1.6N1466TEIEE13DIII S6N1459hNa~v~1.6I1479VEIEE13DIII - DIVI1472hNa~v~1.6E1483KEIEE13DIII - DIVE1476hNa~v~1.6I1583TEIEE13DIV S2-S3V1576hNa~v~1.6V1592LEIEE13DIV S3V1585hNa~v~1.6S1596CEIEE13DIV S3S1589hNa~v~1.6I1605REIEE13DIV S3L1598hNa~v~1.6R1617QEIEE13DIV S4R1610hNa~v~1.6L1621WEIEE13DIV S4L1614hNa~v~1.6A1650TEIEE13DIV S5A1643hNa~v~1.6P1719REIEE13DIV S5-S6P1713hNa~v~1.6N1768DEIEE13DIV S6N1762hNa~v~1.6Q1801EEIEE13C-terminusQ1795hNa~v~1.6E1870DEIEE13C-terminusE1864hNa~v~1.6R1872WEIEE13C-terminusR1866hNa~v~1.6R1872QEIEE13C-terminusR1866hNa~v~1.6R1872LEIEE13C-terminusR1866hNa~v~1.6N1877SEIEE13C-terminusN1871EIEE13: Epileptic encephalopathy, early infantile, 13 Table 8Structural mapping of disease-related mutations identified in human Na~v~1.8Related proteinsMutationsDiseasesStructural positionMap on hNa~v~1.7hNa~v~1.8L554PSFNDI - DII--hNa~v~1.8M650KSFNDI - DIIY729hNa~v~1.8A1304TSFNDIII S5A1344hNa~v~1.8G1662SSFNDIV S5-S6G1699hNa~v~1.8I1706VSFNDIV S6I1744SFN: Small fiber neuropathy Table 9Structural mapping of disease-related mutations identified in human Na~v~1.9Related proteinsMutationsDiseasesStructural positionMap on hNa~v~1.7hNa~v~1.9R222HFEPS3DI S4R214hNa~v~1.9R222SFEPS3DI S4R214hNa~v~1.9R225CFEPS3DI S4R217hNa~v~1.9I381TFEPS3DI S6V383hNa~v~1.9G699RFEPS3DII S5G864hNa~v~1.9A808GFEPS3DII S6A965hNa~v~1.9L811PHSAN7DII S6L968hNa~v~1.9L1158PFEPS3DIII S4L1301hNa~v~1.9V1184AHSAN7DIII S5V1327FEPS3: Episodic pain syndrome, familial, 3; HSAN7: Neuropathy, hereditary sensory and autonomic, 7 Table 10Summary of sodium channelopathiesRelated proteinsDiseaseshNa~v~1.1**GEFS+2**: Generalized epilepsy with febrile seizures plus 2**EIEE6**: Epileptic encephalopathy, early infantile, 6**ICEGTC**: Intractable childhood epilepsy with generalized tonic-clonic seizures**FHM3**: Migraine, familial hemiplegic, 3**FEB3A**: Febrile seizures, familial, 3AhNa~v~1.2**BFIS3**: Seizures, benign familial infantile 3**EIEE11**: Epileptic encephalopathy, early infantile, 11**DS**: Dravet syndromehNa~v~1.3**CPE**: Cryptogenic partial epilepsyhNa~v~1.4**PMC**: Paramyotonia congenita of von Eulenburg**HOKPP2**: Periodic paralysis hypokalemic 2**HYPP**: Periodic paralysis hyperkalemic**NKPP**: Periodic paralysis normokalemic**MYOSCN4A**: Myotonia SCN4A-related**CMS16**: Myasthenic syndrome, congenital, 16hNa~v~1.5**PFHB1A**: Progressive familial heart block 1A**LQT3**: Long QT syndrome 3**BRGDA1**: Brugada syndrome 1**SSS1**: Sick sinus syndrome 1**VF1**: Familial paroxysmal ventricular fibrillation 1**SIDS**: Sudden infant death syndrome**ATRST1**: Atrial standstill 1**CMD1E**: Cardiomyopathy, dilated 1E**ATFB10**: Atrial fibrillation, familial, 10**MEPPC**: Multifocal ectopic Purkinje-related premature contractionhNa~v~1.6**EIEE13**: Epileptic encephalopathy, early infantile, 13hNa~v~1.7**IEM**: Primary erythermalgia**PEPD**: Paroxysmal extreme pain disorder**CIP**: Indifference to pain, congenital, autosomal recessive**DS**: Dravet syndrome**SFN**: Small fiber neuropathy**FEB**: Febrile eizureshNa~v~1.8**SFN**: Small fiber neuropathyhNa~v~1.9**FEPS3**: Episodic pain syndrome, familial, 3**HSAN7**: Neuropathy, hereditary sensory and autonomic, 7

Despite significant advancement in the understanding of Na~v~ channel functions and their relevance to diseases, structural characterization of mammalian Na~v~ channels at atomic level has been challenging, partly due to the substantial technical hurdles in producing mammalian Na~v~ channel proteins in sufficient amount with acceptable purity. The two published bacterial Na~v~ channel crystal structures, Na~v~Ab (Payandeh et al., [@CR49]) and Na~v~Rh (Zhang et al., [@CR71]), in their full-length have greatly improved our understanding of how those channels conduct and select sodium ions on a structural basis. This is further enhanced by the recently published cryo-electron microscopy (cryo-EM) structure of the rabbit voltage-gated calcium (Ca~v~) channel Ca~v~1.1 (Wu et al., [@CR66]; Wu et al., [@CR67]), which, given the significant similarities between Ca~v~ and Na~v~ channels, provides an excellent base model for studying the structure and function of the mammalian Na~v~ channels in lieu of the elusive Na~v~ channel structure (Wu et al., [@CR66]; Wu et al., [@CR67]). In this Resource article, we have built a structure model of the human sodium channel Na~v~1.7 based on the Ca~v~1.1 cryo-EM structure (PDB code: 5GJV). Disease-related mutations of various Na~v~ channels are systematically mapped onto this Na~v~1.7 structural model. As expected, most mutations are located in the VSDs and the pore domain, which corroborate the functional disturbance associated with the various conditions. The human Na~v~1.7 structure model may also provide a useful tool for the structure-based design of drugs that are able to therapeutically target the Na~v~ channels.

STRUCTURE MODEL OF HUMAN SODIUM CHANNEL Na~v~1.7 {#Sec2}
================================================

Homology models of the mammalian Na~v~ channels have been previously constructed based on the crystal structures of the eukaryotic potassium channels or the prokaryotic sodium channels (Tikhonov and Zhorov, [@CR59]; Yang et al., [@CR68]). However, the relevance of such models has been in question, since the eukaryotic sodium channels are known to be heterotetrameric while the prokaryotic sodium channels and the potassium channels are of homotetrameric nature.

We sought to build a homology-based structural model for human Na~v~1.7 because of the tremendous interest in drug development targeting this channel. The sequence identity and similarity between human Na~v~1.7 and rabbit Ca~v~1.1 are 21 and 35%, respectively (Please refer to the online Supplementary Fig. 2 of Wu et al., [@CR67]). Importantly, the key amino acids within the VSDs and the pore domains are highly conserved (Wu et al., [@CR66]; Wu et al., [@CR67]). The cryo-EM structure of rabbit Ca~v~1.1 was then used as the template for homology modeling of human Na~v~1.7. The primary sequence of human Na~v~1.7 was aligned with rabbit Ca~v~1.1 in MOE with manual adjustment when necessary. The structure model of human Na~v~1.7 was created with the Homology Model module in MOE using the GB/VI scoring function with AMBER12:EHT force field (MOE, [@CR47]).

The human Na~v~1.7 model structure resembles the structure of rCa~v~1.1 in general (Fig. [1](#Fig1){ref-type="fig"}A). However, the model exhibits pronounced differences from the calcium channel and bacterial sodium channels particularly in selectivity filter. The SF of Na~v~1.7 consists of four different amino acid residues DEKA (Fig. [1](#Fig1){ref-type="fig"}B). In contrast, the Ca~v~1.1 SF is constituted by four repeated essential glutamic acids, EEEE, while Na~v~Ab and Na~v~Rh contain TLESWS or TLSSWE in each protomer, respectively. This human Na~v~1.7 structure model represents the first one-chain sodium channel model with asymmetric repeats and is expected to shed new light on the mammalian sodium channel functions.Figure 1Homology model structure of human Na~v~1.7 sodium channel. (A) Intra-membrane view and extracellular view of the structure model of Na~v~1.7. The four domains are colored green, light blue, cyan, and gray for domain I, II, III, and IV, respectively. (B) The pore domain of Na~v~1.7 structure model. The S5--S6 segments of Na~v~1.7 are shown and the four selectivity filter amino acids are shown as sticks (left). A close-up view of the four SF residues, D361 in domain I, E927 in domain II, K1406 in domain III, and A1698 in domain IV (right)

MAPPING OF DISEASE-RELEVANT MUTATIONS ONTO THE Na~v~1.7 STRUCTURE MODEL {#Sec3}
=======================================================================

Human Na~v~1.7 sodium channel is preferentially expressed in the sensory neurons of dorsal root ganglia and sympathetic ganglia neurons, particularly within the nociceptors, which is essential for perceiving pain (Djouhri et al., [@CR17]; Dib-Hajj et al., [@CR16]). To date, about 60 mutations of Na~v~1.7 have been found to cause human pain syndromes including IEM, PEPD, CIP, SFN (small fiber neuropathy), DS (Dravet syndrome), and FEB (febrile seizure) (Fig. [2](#Fig2){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). We mapped all the reported Na~v~1.7 mutations onto this Na~v~1.7 structure model (Fig. [2](#Fig2){ref-type="fig"}). Nineteen out of 22 IEM mutations are located in the highly conserved regions of VSDs and the pore domain except for the Q10R, P610T, and G616R mutations (Fig. [2](#Fig2){ref-type="fig"}). Electrophysiology study showed that IEM mutations cause a prominent shift of the activation voltage toward a more negative region or delay deactivation, which results in neuron hyperexcitability (Choi et al., [@CR9]; Lampert et al., [@CR36]; Choi et al., [@CR10]; Lampert et al., [@CR37]). For example, mutation of A1643 within the S5 segment of domain IV to glycine (A1643G) generates a significant hyperpolarizing shift (Yang et al., [@CR69]). Our structural analysis shows that only two IEM mutations F216S and L834R are located in the S4 positively charged segment that is directly responsible for transmembrane voltage sensing and channel activation. How other IEM mutations influence voltage sensing and channel functions is yet to be elucidated.Figure 2Amino acid locations of Na~v~1.7 disease-related mutations on the Na~v~1.7 structure model. (A) The topology of human Na~v~1.7 sodium channel. Cylinders represent the transmembrane segments, which are colored in gray except that the S4 voltage-sensing segments are colored in yellow. The lines represent the soluble regions between the transmembrane segments or the N/C-terminus. The two P helices between S5 and S6 segments are shown in cylinders. Mutations of Na~v~1.7 are discriminately mapped on the topology scheme of Na~v~1.7 by different colors, namely, IEM (blue), PEPD (red), CIP (cyan), DS (purple), SFN (green), and FEB (pink). (B) Intra-membrane view and intracellular views of the Na~v~1.7 structure model. Mapping of disease-related mutations onto the Na~v~1.7 structure model is highlighted by different colors. Summary of Na~v~1.7 mutations is shown in different gray boxes

The PEPD mutations are mostly characterized (nine out of 11) within the S4 segment, S4-S5 linker region, and the cytosolic regions of domain III and domain IV of Na~v~1.7 except for R185H and R1007C (Fig. [2](#Fig2){ref-type="fig"}A and Table [1](#Tab1){ref-type="table"}). Specifically, I1472T, F1473V, and T1475I are within the IFMT motif (Fig. [2](#Fig2){ref-type="fig"}A), indicating that they may disturb channel inactivation. Indeed, IFMT mutations usually impair fast inactivation with consequently persistent currents (Fertleman et al., [@CR24]). The V1309D, V1309F, and V1310F mutations are located in the S4-S5 linker region of domain III and they have been shown to cause moderate destabilization of fast inactivation (Jarecki et al., [@CR33]). The G1618R mutation, located within the S4 segment of domain IV, impairs inactivation and retains a persistent current compared to the wild-type (WT) channel (Choi et al., [@CR11]), while another domain IV S4 segment mutation, L1623P, significantly increases ramp current and shortens recovery time from inactivation (Suter et al., [@CR56]). Moreover, electrophysiology study showed that M1638K mutation (within the S5 segment of domain IV) generates faster recovery from inactivation than the WT channel, producing greater currents and reducing the threshold with increased number of action potentials (Fertleman et al., [@CR24]; Dib-Hajj et al., [@CR15]). Another PEPD mutation, A1643E, also located in the S5 segment of domain IV, impedes channel full inactivation, which results in persistent inward currents (Estacion et al., [@CR19]).

The CIP patients, characterized by lack of nociceptive perception, are mostly inflicted by Na~v~1.7 nonsense mutations, which result in premature protein truncations and inability to produce functional sodium channels. Only three mutations of Na~v~1.7, namely R907Q, A1247E, and W1786R, have been reported to be associated with CIP (Fig. [2](#Fig2){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). Diseases such as DS, SFN, and FEB are also known to be caused by Na~v~1.7 mutations (Fig. [2](#Fig2){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). For example, all eight SFN mutations have been characterized. Specifically, I228M, I731K, I750V, and M1543I mutations impair slow inactivation, D623N impedes slow and fast inactivation, while R185H, M943L, and V1002L mutations enhance resurgent currents (Faber et al., [@CR22]). On the other hand, Na~v~1.7 mutations that are associated with DS (nine mutations) and FEB (six mutations) have not been well characterized.

MAPPING OF OTHER HUMAN SODIUM CHANNEL DISEASE-RELATED MUTATIONS ONTO THE Na~v~1.7 STRUCTURE MODEL {#Sec4}
=================================================================================================

Members of the human Na~v~ channel family share high sequence similarity and mutations of these Na~v~ channels are known to cause a vast variety of channelopathies. In order to better understand the role of those mutations in disturbing normal channel functions on a structural level, we mapped the disease-related mutations of other human Na~v~ channels onto the Na~v~1.7 structure model based on the sequence alignment reported in Wu et al., [@CR67] (Fig. [3](#Fig3){ref-type="fig"}).Figure 3Mapping of Na~v~ channel disease-related mutations onto the Na~v~1.7 structure model. The Na~v~1.7 channel is shown in cartoon from the intra-membrane view. The Cα atoms of the disease-related amino acids are shown in spheres. Mapped mutations from nine Na~v~ sodium channels to the Na~v~1.7 structure model are differentiated by distinct colors, Na~v~1.1 (A, blue), Na~v~1.2 (B, cyan), Na~v~1.3 (C, magenta), Na~v~1.4 (D, purple blue), Na~v~1.5 (E, pale cyan), Na~v~1.6 (F, orange), Na~v~1.7 (G, red), Na~v~1.8 (H, green), and Na~v~1.9 (I, salmon)

Among all the nine Na~v~ channels, Na~v~1.1 and Na~v~1.5 have the largest numbers of reported mutations (more than 400 each) (Fig. [3](#Fig3){ref-type="fig"}A and [3](#Fig3){ref-type="fig"}E), while Na~v~1.3, Na~v~1.8, and Na~v~1.9 have the least numbers (less than 10 each) (Fig. [3](#Fig3){ref-type="fig"}C, [3](#Fig3){ref-type="fig"}H, and [3](#Fig3){ref-type="fig"}I). Notably, mutations in Na~v~1.1, Na~v~1.2, Na~v~1.3, and Na~v~1.6 mainly cause epilepsies; those in Na~v~1.4 are related to myopathies; in Na~v~1.5 result in cardiac channelopathies; and in Na~v~1.7, Na~v~1.8, and Na~v~1.9 are associated with pain-related diseases (Fig. [3](#Fig3){ref-type="fig"} and Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}, [9](#Tab9){ref-type="table"}, [10](#Tab10){ref-type="table"}). Mapping of all Na~v~ channel mutations onto the Na~v~1.7 structure model revealed that more than 80% of mutations are located in the VSDs and pore domains (Fig. [4](#Fig4){ref-type="fig"}A and [4](#Fig4){ref-type="fig"}B). Notably, disease-causing mutations are somewhat equally distributed in all four Na~v~ channel domains, which account for more than 20 sodium channelopathies (Fig. [4](#Fig4){ref-type="fig"}C). Furthermore, mutations are also distributed in various regions of the pore domains, suggesting that they may disturb Na~v~ channel functions by altering sodium ion selectivity and conductivity (Fig. [4](#Fig4){ref-type="fig"}D).Figure 4Mutations that cause sodium channelopathies are plotted on the Na~v~1.7 sodium channel model. (A) The amino acid residues related with sodium channelopathies are mapped on the Na~v~1.7 structure model. All mutated residues are shown in spheres and colored for Na~v~1.1 (blue), Na~v~1.2 (cyan), Na~v~1.3 (magenta), Na~v~1.4 (purple blue), Na~v~1.5 (pale cyan), Na~v~1.6 (orange), Na~v~1.7 (red), Na~v~1.8 (green), and Na~v~1.9 (salmon). (B) The distribution of sodium channelopathy-related mutations on the transmembrane regions of the Na~v~1.7 structure model. Mutations of the VSDs and the pore domain are shown from the intra-membrane and intracellular views. (C) The mutation distributions for the four domains. S1--S6 segments are shown in cylindrical helices. (D) Mapping mutations to the pore domain in four different views

Na~v~1.2 mutations are largely associated with various epilepsy diseases, including BFIS3 (seizures, benign familial infantile 3), EIEE11 (epileptic encephalopathy, early infantile, 11), and DS (Fig. [3](#Fig3){ref-type="fig"}B and Table [3](#Tab3){ref-type="table"}). More than 30 Na~v~1.2 mutations have been discovered and some of them are now functionally characterized. Interestingly, electrophysiological studies showed that Na~v~1.2 mutations can either be loss-of-function (R1319Q and L1330F) or gain-of-function (M252V, V261M, L1563V, and Y1579C) (Misra et al., [@CR46]; Liao et al., [@CR42]; Lauxmann et al., [@CR39]). It is noted that BFIS3 mutations in Na~v~1.2 create less pronounced changes in the activation and inactivation potentials than the EIEE11 mutations (Shi et al., [@CR52]).

Only six missense mutations of Na~v~1.3 have so far been identified in patients with cryptogenic partial epilepsy (Fig. [3](#Fig3){ref-type="fig"}C and Table [4](#Tab4){ref-type="table"}). Five of them, namely K354Q, R357Q, D815N, E1160K, and M1372V, have been characterized, all of which are gain-of-function mutations, consistent with the neuronal hyperexcitability phenotype (Estacion et al., [@CR20]; Vanoye et al., [@CR60]).

Na~v~1.4 is essential for controlling the muscle action potential and consequently crucial for skeletal muscle contraction. Mutations of Na~v~1.4 are related with various neuromuscular disorders including PMC (paramyotonia congenita of von Eulenburg), HOKPP2 (periodic paralysis hypokalemic 2), HYPP (periodic paralysis hyperkalemic), NKPP (periodic paralysis normokalemic), MYOSCN4A (myotonia SCN4A-related), and CMS16 (myasthenic syndrome, congenital, 16) (Fig. [3](#Fig3){ref-type="fig"}D and Table [5](#Tab5){ref-type="table"}). Different disease-causing mutations alter the Na~v~1.4 channel function through distinct mechanisms. For example, CMS16 mutations R104H, P382T, and C1209F completely abolish the Na~v~1.4 channel's ability to conduct sodium ion, while other mutations such as M203K, R225W, and D1069N cause reduced action potential amplitude, leading to impaired channel function (Zaharieva et al., [@CR70]). Compared to the WT channel, a CMS16 voltage sensor mutant R1457H requires longer hyperpolarization to recover which results in increased fast inactivation (Arnold et al., [@CR1]). On the other hand, a HOKPP2 mutation R1135H (the third arginine in the domain III voltage sensor) exhibits increased depolarization, suggesting that R1135H mutation be gain-of-function (Groome et al., [@CR27]). A MYOSCN4A mutation I582V shows a hyperpolarizing shift of 6 mV, indicating the nature of this mutation be also gain-of-function (Corrochano et al., [@CR12]).

Na~v~1.6 is one of the sodium channels expressed in human brain and mutations of Na~v~1.6 cause EIEE13 (epileptic encephalopathy, early infantile, 13) (Fig. [3](#Fig3){ref-type="fig"}F and Table [7](#Tab7){ref-type="table"}). More than 40 Na~v~1.6 mutations have been discovered since 2012 (Fig. [3](#Fig3){ref-type="fig"}F and Table [7](#Tab7){ref-type="table"}), and seven of them have been studied in the functional assays. Specifically, five Na~v~1.6 mutations, namely T767I, N984K, T1716I, N1768D, and R1872W/R1872Q/R1872L, are characterized as gain-of-function, which cause hyperpolarizing shift of inactivation voltage or increased persistent current (Veeramah et al., [@CR62]; Estacion et al., [@CR21]; Wagnon et al., [@CR64]), while the other two mutations, R223G and G1451S, are loss-of-function (de Kovel et al., [@CR14]; Blanchard et al., [@CR2]).

Five Na~v~1.8 mutations are associated with SFN, a condition that is clinically characterized by autonomic dysfunction and burning pain in the distal extremities (Fig. [3](#Fig3){ref-type="fig"}H and Table [8](#Tab8){ref-type="table"}). Electrophysiology study has shown that Na~v~1.8 mutations, specifically L554P, A1304T, G1662S, and I1706V, accelerate inactivation recovery and enhance activation, which result in hyperexcitability (Faber et al., [@CR23]; Huang et al., [@CR31]; Han et al., [@CR28]). However, another SFN Na~v~1.8 mutation M650K causes reduced excitability of C fibers (Kist et al., [@CR35]).

FEPS3 (episodic pain syndrome, familial, 3) and HSAN7 (neuropathy, hereditary sensory and autonomic, 7) are thought to be caused by the nine missense gain-of-function mutations of Na~v~1.9 (Fig. [3](#Fig3){ref-type="fig"}I and Table [9](#Tab9){ref-type="table"}). Specifically, compared to the WT channel, R225C and A808G mutations induce hyperexcitability of the DRG neurons (Zhang et al., [@CR72]), G699R enhances activation (Han et al., [@CR29]), L811P significantly increases current density (Leipold et al., [@CR40]), L1158P enhances spontaneous firing (Huang et al., [@CR32]), and V1184A alters the channel voltage dependence that results in channel opening in response to hyperpolarized potentials (Leipold et al., [@CR41]).

DISEASE-RELATED MUTATIONS IN SODIUM CHANNELS Na~v~1.1 AND Na~v~1.5 {#Sec5}
==================================================================

Mutations of Na~v~1.1 are associated with several neurological disorders including GEFS+2, EIEE6, ICEGTC, FHM3 (migraine, familial hemiplegic, 3), and FEB3A (febrile seizures, familial, 3A) (Table [2](#Tab2){ref-type="table"} and Table [10](#Tab10){ref-type="table"}). More than 400 mutations of Na~v~1.1 have been identified, approximately 10% account for GEFS+2 while 80% for EIEE6 (Fig. [5](#Fig5){ref-type="fig"}A and Table [2](#Tab2){ref-type="table"}). By mapping the Na~v~1.1-related mutations to the Na~v~1.7 structure model, we identified that most mutations are located in the VSDs and the pore domain (Fig. [5](#Fig5){ref-type="fig"}A). For example, mutations of the four positively charged residues, R1639G, R1642S, R1645Q, and R1648C, are present in the domain IV S4 segment (Table [2](#Tab2){ref-type="table"}), suggesting that these EIEE6 mutations may alter the voltage sensing behavior of the channel. In addition, it is noteworthy that Na~v~1.1 mutations can be either loss-of-function or gain-of-function (Catterall et al., [@CR8]; Escayg and Goldin, [@CR18]). For example, two GEFS+2 mutations W1204R and R1648H increase the level of persistent current through gain-of-function (Lossin et al., [@CR43]), while the loss-of-function M145T mutation in FEB3A decreases 60% of the current density (Mantegazza et al., [@CR45]).Figure 5Distributions of the missense mutations in Na~v~1.1 and Na~v~1.5. (A) Distributions of Na~v~1.1 missense mutations on the Na~v~1.7 model structure. More than 400 mutations are mapped. Mutations from five Na~v~1.1-related diseases are shown from intra-membrane, intracellular, and extracellular views. The Na~v~1.7 model is shown in cylindrical helices and colored by GEFS+2 in red, EIEE6 in blue, ICEGTC in cyan, FHM3 in green, and FEB3A in yellow. (B) Distributions of Na~v~1.5 related-disease mutations on the Na~v~1.7 structure model. Mutations from Na~v~1.5 related diseases are shown from intra-membrane, intracellular, and extracellular views. Different diseases are colored in green for PFHB1A, blue for LQT3, red for BRGDA1, cyan for SSS1, and magenta for VF1, SIDS, ATRST1, CMD1E, ATFB10, and MEPPC

Na~v~1.5 is the primary sodium channel in the heart and is essential for the cardiac action potential initiation. More than 400 Na~v~1.5 mutations have been discovered and they are implicated in a wide variety of cardiac diseases---including PFHB1A (progressive familial heart block 1A), LQT3, BRGDA1, SSS1, VF1 (familial paroxysmal ventricular fibrillation 1), SIDS (sudden infant death syndrome), ATRST1 (atrial standstill 1), CMD1E (cardiomyopathy, dilated 1E), ATFB10 (atrial fibrillation, familial, 10), and MEPPC (multifocal ectopic Purkinje-related premature contractions) (Fig. [5](#Fig5){ref-type="fig"}B and Table [6](#Tab6){ref-type="table"}). By mapping all the Na~v~1.5 mutations onto the Na~v~1.7 structure model, it shows that most mutations are located in the transmembrane regions of the channel, suggesting that these mutations might disturb voltage sensing or sodium conduction (Fig. [5](#Fig5){ref-type="fig"}B). Furthermore, about 50% of the Na~v~1.5 mutations account for BRGDA1, while 30% for LQT3. Similar to the case of Na~v~1.1, mutations in Na~v~1.5 can be either loss-of-function or gain-of-function. For example, loss-of-function mutations are associated with BRGDA1, CMD1E, SSS1, and ATFB10 (Tan et al., [@CR58]; Smits et al., [@CR53]; Makiyama et al., [@CR44]; Laurent et al., [@CR38]), while gain-of-function mutations of Na~v~1.5 are responsible for LQT3 (Remme et al., [@CR51]), CMD1E, and ATFB10 (Olson et al., [@CR48]), and most recently MEPPC (Swan et al., [@CR57]).

CONCLUDING REMARKS {#Sec6}
==================

The Na~v~ family of sodium channels are important drug targets for the pharmaceutical industry. However, no atomic structure of any mammalian Na~v~ channels is currently available, preventing the establishment of an in-depth structure-function relationship for this important group of sodium channels and application of structure-based approach to rationally design compounds that are able to modulate the functions of those Na~v~ channels in a disease relevant manner. Using the recently published cryo-EM structure of a rabbit Ca~v~ channel Ca~v~1.1, we established an atomic level heterotetrameric structure model for the human Na~v~ channel Na~v~1.7. Disease-related mutations of Na~v~1.7 and other members of the Na~v~ family, which are largely responsible for many neurological disorders like epilepsies, pains, and myopathies, are mapped onto the structure model. Taken together the available functional data, we attempted to establish a rudimentary structure-function relationship for human Na~v~1.7 and other members of the Na~v~ channel family. It is noticeable that sodium channelopathies can be attributed to both loss-of-function and gain-of-function mutations.

However, we must realize that the current Na~v~1.7 structural model has its limitation and the atomic resolution mammalian Na~v~ channel structure is urgently needed. In recent years, cryo-EM technology is becoming a mainstream technology for structural biology, which is able to potentially overcome the significant technical hurdles in producing challenging proteins such as mammalian Na~v~ channels in sufficient quality and the necessity of crystallization for structural elucidation. Detailed mechanisms of how the Na~v~ channels sense voltage changes and conduct sodium ions can only be answered when such atomic resolution structures become available. We hope the Na~v~1.7 structure model presented here is a temporary surrogate to help understand the Na~v~ channel functions, particularly those relevant to the various neurological diseases, at atomic level, and contributes to the structure-based rational design of the next generation Na~v~ channel modulators.

SUMMARY OF DISEASE-RELATED MUTATIONS FOR SODIUM CHANNELS {#Sec7}
========================================================

Most of the Na~v~ channel disease-related mutations are extracted from the UNIPROT websites:

<http://www.uniprot.org/uniprot/P35498> (Na~v~1.1);

<http://www.uniprot.org/uniprot/Q99250> (Na~v~1.2);

<http://www.uniprot.org/uniprot/P35499> (Na~v~1.4);

<http://www.uniprot.org/uniprot/Q14524> (Na~v~1.5);

<http://www.uniprot.org/uniprot/Q9UQD0> (Na~v~1.6);

<http://www.uniprot.org/uniprot/Q15858> (Na~v~1.7);

<http://www.uniprot.org/uniprot/Q9Y5Y9> (Na~v~1.8);

<http://www.uniprot.org/uniprot/Q9UI33> (Na~v~1.9).

In the UNIPROT websites, there are no mutations described for Na~v~1.3. During literatures searching, we found that six mutations of Na~v~1.3 are associated with cryptogenic partial epilepsy. Except for the present mutations in the UNIPROT websites, we found additional mutations of Na~v~ channels in literatures. All mutations are summarized in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}, [9](#Tab9){ref-type="table"}. However, we recognize that our summary may not contain all Na~v~ channel disease-related mutations owing to abundant literatures reporting Na~v~ channel disease-related mutations and increasing volume of work describing new findings.
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ABBREVIATIONS {#FPar1}
=============

ATRST1, atrial standstill 1; BRGDA1, Brugada syndrome 1; Ca~v~, voltage-gated calcium; CNS, central nervous system; cryo-EM, cryo-electron microscopy; DS, Dravet syndrome; FEB, febrile seizure; GEFS+2, generalized epilepsy with febrile seizures plus 2; HOKPP2, periodic paralysis hypokalemic 2; HYPP, periodic paralysis hyperkalemic; IEM, primary erythermalgia; LQT3, long QT syndrome 3; MEPPC, multifocal ectopic Purkinje-related premature contractions; Na~v~, voltage-gated sodium; NKPP, periodic paralysis normokalemic; PEPD, paroxysmal extreme pain disorder; PFHB1A, progressive familial heart block 1A; PMC, paramyotonia congenita of von Eulenburg; SF, selectivity filter; SFN, small fiber neuropathy; SIDS, sudden infant death syndrome; SSS1, sick sinus syndrome 1; VF1, familial paroxysmal ventricular fibrillation 1; VSDs, voltage-sensing domains
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